ESC 2015:PCI患者经桡动脉途径优于经股动脉(ISACS-TC注册研究)

2015-09-08 河北医科大学第二医院 傅向华 肖宇杨 编译 中国医学论坛报

近期随机研究已经证实,对于急性冠脉综合征(ACS)患者,与经股动脉途径行经皮冠状动脉支架置入术(PCI)相比,经桡动脉途径可降低局部穿刺血管并发症和出血的发生。 本次ESC大会上欧洲学者展示的一项壁报研究比较了ACS患者行经桡动脉与经股动脉途径PCI后发生院内事件情况,结果显示,两组患者院内死亡率未见明显差异,但经桡动脉途径患者围手术期并发症相对较

近期随机研究已经证实,对于急性冠脉综合征(ACS)患者,与经股动脉途径行经皮冠状动脉支架置入术(PCI)相比,经桡动脉途径可降低局部穿刺血管并发症和出血的发生。

本次ESC大会上欧洲学者展示的一项壁报研究比较了ACS患者行经桡动脉与经股动脉途径PCI后发生院内事件情况,结果显示,两组患者院内死亡率未见明显差异,但经桡动脉途径患者围手术期并发症相对较少。

研究数据来源于ISACS-TC注册研究,其为一项对于ACS患者为期5年的回顾性研究(2010.1-2015.1)。观察事件包括:患者院内死亡,以及作为复合终点包括4型心肌梗死、血管突然闭塞(4b型)、侧枝堵塞、远端血管栓塞以及无复流等围手术期主要并发症。

结果为,在6006例ACS行PCI患者中,3656例患者(60.9%)行经桡动脉途径手术,入组患者男性居多,患者较年轻并且危险因素相对较少。经桡动脉途径患者围手术期并发症相对较少 (3.4%对10.3%, P<0.001)。结合统计学和临床特征,围手术期风险降低40%[比值比(OR)为0.60,95%可信区间(CI)为 0.45–0.81)。经桡动脉途径患者院内死亡率为3.1%,经股动脉途径患者为4.0%(未调整OR为0.76, 95% CI为0.57–1.00)。该结果经多变量调整后无差异 (OR=1.06, 95%CI为0.75–1.48)。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1931761, encodeId=d8811931e610a, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Oct 31 04:05:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786803, encodeId=9b771e868030d, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Thu Dec 10 02:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691191, encodeId=6ac7169119178, content=<a href='/topic/show?id=320ee8456be' target=_blank style='color:#2F92EE;'>#经股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78456, encryptionId=320ee8456be, topicName=经股动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efdf29169795, createdName=d830382, createdTime=Sun Sep 27 15:05:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010595, encodeId=d0e8201059500, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Apr 24 06:05:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764753, encodeId=123b1e64753bb, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Tue Apr 05 18:05:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279111, encodeId=33d512e911169, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441086, encodeId=90ea144108648, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556723, encodeId=dc131556e23ee, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1931761, encodeId=d8811931e610a, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Oct 31 04:05:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786803, encodeId=9b771e868030d, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Thu Dec 10 02:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691191, encodeId=6ac7169119178, content=<a href='/topic/show?id=320ee8456be' target=_blank style='color:#2F92EE;'>#经股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78456, encryptionId=320ee8456be, topicName=经股动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efdf29169795, createdName=d830382, createdTime=Sun Sep 27 15:05:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010595, encodeId=d0e8201059500, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Apr 24 06:05:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764753, encodeId=123b1e64753bb, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Tue Apr 05 18:05:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279111, encodeId=33d512e911169, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441086, encodeId=90ea144108648, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556723, encodeId=dc131556e23ee, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-12-10 zhmscau
  3. [GetPortalCommentsPageByObjectIdResponse(id=1931761, encodeId=d8811931e610a, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Oct 31 04:05:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786803, encodeId=9b771e868030d, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Thu Dec 10 02:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691191, encodeId=6ac7169119178, content=<a href='/topic/show?id=320ee8456be' target=_blank style='color:#2F92EE;'>#经股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78456, encryptionId=320ee8456be, topicName=经股动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efdf29169795, createdName=d830382, createdTime=Sun Sep 27 15:05:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010595, encodeId=d0e8201059500, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Apr 24 06:05:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764753, encodeId=123b1e64753bb, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Tue Apr 05 18:05:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279111, encodeId=33d512e911169, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441086, encodeId=90ea144108648, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556723, encodeId=dc131556e23ee, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1931761, encodeId=d8811931e610a, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Oct 31 04:05:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786803, encodeId=9b771e868030d, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Thu Dec 10 02:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691191, encodeId=6ac7169119178, content=<a href='/topic/show?id=320ee8456be' target=_blank style='color:#2F92EE;'>#经股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78456, encryptionId=320ee8456be, topicName=经股动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efdf29169795, createdName=d830382, createdTime=Sun Sep 27 15:05:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010595, encodeId=d0e8201059500, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Apr 24 06:05:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764753, encodeId=123b1e64753bb, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Tue Apr 05 18:05:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279111, encodeId=33d512e911169, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441086, encodeId=90ea144108648, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556723, encodeId=dc131556e23ee, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1931761, encodeId=d8811931e610a, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Oct 31 04:05:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786803, encodeId=9b771e868030d, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Thu Dec 10 02:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691191, encodeId=6ac7169119178, content=<a href='/topic/show?id=320ee8456be' target=_blank style='color:#2F92EE;'>#经股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78456, encryptionId=320ee8456be, topicName=经股动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efdf29169795, createdName=d830382, createdTime=Sun Sep 27 15:05:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010595, encodeId=d0e8201059500, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Apr 24 06:05:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764753, encodeId=123b1e64753bb, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Tue Apr 05 18:05:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279111, encodeId=33d512e911169, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441086, encodeId=90ea144108648, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556723, encodeId=dc131556e23ee, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1931761, encodeId=d8811931e610a, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Oct 31 04:05:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786803, encodeId=9b771e868030d, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Thu Dec 10 02:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691191, encodeId=6ac7169119178, content=<a href='/topic/show?id=320ee8456be' target=_blank style='color:#2F92EE;'>#经股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78456, encryptionId=320ee8456be, topicName=经股动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efdf29169795, createdName=d830382, createdTime=Sun Sep 27 15:05:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010595, encodeId=d0e8201059500, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Apr 24 06:05:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764753, encodeId=123b1e64753bb, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Tue Apr 05 18:05:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279111, encodeId=33d512e911169, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441086, encodeId=90ea144108648, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556723, encodeId=dc131556e23ee, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 yaanren
  7. [GetPortalCommentsPageByObjectIdResponse(id=1931761, encodeId=d8811931e610a, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Oct 31 04:05:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786803, encodeId=9b771e868030d, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Thu Dec 10 02:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691191, encodeId=6ac7169119178, content=<a href='/topic/show?id=320ee8456be' target=_blank style='color:#2F92EE;'>#经股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78456, encryptionId=320ee8456be, topicName=经股动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efdf29169795, createdName=d830382, createdTime=Sun Sep 27 15:05:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010595, encodeId=d0e8201059500, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Apr 24 06:05:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764753, encodeId=123b1e64753bb, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Tue Apr 05 18:05:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279111, encodeId=33d512e911169, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441086, encodeId=90ea144108648, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556723, encodeId=dc131556e23ee, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1931761, encodeId=d8811931e610a, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Oct 31 04:05:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786803, encodeId=9b771e868030d, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Thu Dec 10 02:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691191, encodeId=6ac7169119178, content=<a href='/topic/show?id=320ee8456be' target=_blank style='color:#2F92EE;'>#经股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78456, encryptionId=320ee8456be, topicName=经股动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efdf29169795, createdName=d830382, createdTime=Sun Sep 27 15:05:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010595, encodeId=d0e8201059500, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Apr 24 06:05:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764753, encodeId=123b1e64753bb, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Tue Apr 05 18:05:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279111, encodeId=33d512e911169, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441086, encodeId=90ea144108648, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556723, encodeId=dc131556e23ee, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 zhyy93

相关资讯

ESC 2015:LCZ696能多途径降低老年人血压和脉压(PARAMETER研究)

8月31日,在欧洲心脏病学会(ESC)年会的“Hot Line IV-高血压”专场PARAMETER研究结果公布。这项随机对照研究显示,与ARB类药物奥美沙坦相比,血管紧张素受体脑啡肽酶抑制剂LCZ696(缬沙坦/sacubitril)可显著降低老年高血压患者的血压和脉压水平。首席研究员Bryan Williams(伦敦大学)表示,LCZ696可能在心脏病、卒中和心力衰竭预防中提供更大的保护作用。

ESC 2015:年轻糖尿病女性心脏病的发病风险可高达6倍

年轻糖尿病女性心脏病的发病风险可高达6倍研究发现年轻糖尿病女性可有高达6倍的心脏病发病风险,研究共纳入了7000名45岁及以下的女性。研究还指出,论心脏病的发病风险,吸烟较老龄大一些。心血管疾病主要影响老年人群,但是近些年来,年轻人(不分性别)的发病率也越来越高。据WHO统计,心血管疾病所致的女性死亡占女性总死亡的52%,而且这个比例正不断加大。心脏病发作患者中1%为年轻女性。与无MI病史的女性相

ESC 2015:螺内酯——难治性高血压中老树新花(PATHWAY-2研究)

今年ESC 2015年会的高血压Hotline专场,研究者Bryan William教授发布了PATHWAY-2研究的结果。Bryan William教授总结道,本研究第一次证实了螺内酯(25~50mg/d)在治疗难治性高血压方面相对于其他药物绝对优势。对于难治性高血压的控制率几乎达到60%,显著高于其他几组。且其耐受性良好,并未增加不良事件的发生。研究者评价道,该研究结果提示,螺内酯是难治性高血

ESC 2015:心包疾病指南亮点

2015欧洲心脏病学会年会(ESC2015)专题报道1、由于多中心随机对照试验的开展,2004年之后心包疾病的治疗有了长足进展。基于这些研究,秋水仙碱现被推荐为一线治疗药物——在首次发作心包炎或复发心包炎的患者中,秋水仙碱可加强患者对阿司匹林或非甾体抗炎药物的反应。2、指南推荐,对于复发性心包炎的女性患者,应在疾病稳定期计划妊娠。指南还包括对于妊娠20周前/后、产后哺乳期间药物治疗选择的推荐。3、

ESC 2015:左心耳电隔离可抑制长程持续性房颤(BELIEF研究)

ESC2015年会“Hot Line”专题会上公布的BELIEF研究结果显示,对于经过标准治疗但仍有长程持续性房颤的患者,给予额外的左心耳电隔离可减少房颤发生而且不增加并发症。Luigi Di Biase博士(美国德克萨斯St. David's医学中心心律失常研究所)等报告,与标准消融治疗相比,在此基础上加左心耳电隔离可以提高导管消融的远期成功率。BELIEF研究纳入173名长程持续性房颤患者。长

ESC 2015:起搏治疗未能改善大面积心梗患者预后(PRomPT试验)

近日,Gregg. W. Stone(哥伦比亚大学医学中心)等在ESC 2015年会上呈现了PRomPT试验结果。他们发现,左心室导联放置于梗死区起搏治疗未能进一步阻止大面积心肌梗死患者心脏重塑的进展,也没有改善18个月时的功能或临床预后。这一发现可能成为心梗后心脏重塑预防工作的一个转折点,未来研究可能不会进一步对这一领域(左心室起搏改善大面积心梗患者预后)进行探索。对于大面积心肌梗死的患者,药物